Startup · $2.5m raised
Programs: Brandon BioCatalyst (CUREator+) · CUREator+ (CUREator+)
Every investor coverage indicates participated in a round Aleris Therapeutics raised.
| Investor | Rounds | Invested |
|---|---|---|
| Medical Research Future Fund | Grant | - |
| CUREator+ | Accelerator · Grant | - |
| Brandon BioCatalyst | Accelerator · Grant | - |
| ANDHealth | Grant | - |
Companies Aleris Therapeutics acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Aleris Therapeutics. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Six Australian health tech startups received non-dilutive grants totaling $13.5 million from the government-backed CUREator+ program to accelerate commercialisation of medical innovations.
Six Australian biomedical and health ventures receive a combined $13.5 million in non-dilutive grants through round two of the CUREator+ commercialisation program operated by Brandon BioCatalyst and backed by the Medical Research Future Fund.
Also Dealroom
Six Australian health tech startups received a combined $13.5 million in non-dilutive funding from the CUREator+ program, supported by the Australian Government.
CUREator+ granted thirteen point five million dollars in non-dilutive funding to six Australian health tech startups to support commercialisation of medical innovations.